Ser188

Site Information
LGErkPssAAyQkAP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 452069

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 1 ) , mass spectrometry ( 2 , 3 , 4 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:	HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , ovarian cancer ( 3 )
Relevant cell line - cell type - tissue:	breast ( 2 ) , HT-29 (intestinal) ( 1 ) , KMS-11 (B lymphocyte) ( 4 ) , OVKATE (ovarian) ( 3 )

Downstream Regulation
Effects of modification on biological processes:	transcription, induced ( 1 )

References
1	Jang B, et al. (2017) Syndecan-2 cytoplasmic domain up-regulates matrix metalloproteinase-7 expression via the protein kinase Cγ-mediated FAK/ERK signaling pathway in colon cancer. J Biol Chem 292, 16321-16332 28821612 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Ren H (2010) CST Curation Set: 10743; Year: 2010; Biosample/Treatment: cell line, OVKATE/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
4	St-Germain JR, et al. (2009) Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci U S A 106, 20127-32 19901323 Curated Info